Azole Resistance of Environmental and Clinical *Aspergillus fumigatus* Isolates from Switzerland

Arnaud Riat,* Jérôme Plojoux, Katia Gindro, Jacques Schrenzel, Dominique Sanglardd

*Service of Infectious Diseases and Service of Laboratory Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland*

*Division of Pneumology, Geneva University Hospitals, Geneva, Switzerland*

*Agroscope, Strategic Research Division Plant Protection, Mycology and Biotechnology, Nyon, Switzerland*

*Institute of Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland*

**ABSTRACT** *Aspergillus fumigatus* is a ubiquitous opportunistic pathogen. This fungus can acquire resistance to azole antifungals due to mutations in the azole target (*cyp51A*). Recently, *cyp51A* mutations typical for environmental azole resistance acquisition (for example, TR34/L98H) have been reported. These mutations can also be found in isolates recovered from patients. Environmental azole resistance acquisition has been reported on several continents. Here we describe, for the first time, the occurrence of azole-resistant *A. fumigatus* isolates of environmental origin in Switzerland with *cyp51A* mutations, and we show that these isolates can also be recovered from a few patients. While the TR34/L98H mutation was dominant, a single azole-resistant isolate exhibited a *cyp51A* mutation (G54R) that was reported only for clinical isolates. In conclusion, our study demonstrates that azole resistance with an environmental signature is present in environments and patients of Swiss origin and that mutations believed to be unique to clinical settings are now also observed in the environment.

**KEYWORDS** *Aspergillus*, antifungal agents, antifungal resistance, azole

*A. fumigatus* is a common and widespread filamentous fungus. *A. fumigatus* can disperse easily in the environment due to its ability to form conidia. Due to their small diameter, conidia can easily reach the lower respiratory airways of humans. This characteristic makes *A. fumigatus* a cause of several pulmonary diseases in humans, ranging from aspergilloma to allergic bronchopulmonary aspergillosis (ABPA) and various forms of invasive aspergillosis (IA) (1). The treatment of aspergillosis syndrome involves four triazole antifungal drugs: itraconazole (ITZ), voriconazole (VRZ), posaconazole (POS), and isavuconazole (ISA). ITZ was the first orally active drug for aspergillosis (2). VRZ was approved next and showed its superiority to amphotericin B (3). The oral and intravenous availability of VRZ and its positive effects on patients made this drug the first choice for IA in almost all clinical guidelines (4). POS was approved later for the prevention of fungal infection (especially aspergillosis) in leukemia and bone marrow transplant patients and for second-line therapy (5). ISA has been approved more recently for the treatment of IA (6).

The use of antifungal agents is inevitably associated with the occurrence of resistance. After azoles were introduced to treat *A. fumigatus* infections, reports of resistance started to emerge. The first case of azole-resistant *A. fumigatus* reported involved a mutation in the *cyp51A* gene, the target of azoles in this organism. This isolate revealed a single mutation in which methionine at the codon position 220 was replaced by arginine (M220R). A similar mutation, M220I, was recovered from a Swedish patient in 1998. Since then, several other single substitutions in *cyp51A* have been identified (7).
Single substitutions at codons G54, G138, P216, F219, M220, and G448 have been reported (8). In 2007, Mellado et al. (9) identified a novel type of mutation in several pan-azole-resistant clinical isolates associating a single amino acid substitution in cyp51A with a 34-bp tandem repeat in the promoter of the same gene (the TR34/L98H mutation). This type of mutation was next found in the environment, raising the possibility that agricultural azole use could facilitate the dissemination of such resistant strains (10). The TR34/L98H mutation has now been reported at the scale of several continents (11). In addition, the presence of another mutation, TR46/Y121F/T289A, has also been reported in six of nine European countries (12).

Epidemiological data gathered to date show that the frequency of environmental resistance acquisition ranges from 0.5 to 5% in sampled isolates (10). The prevalence of azole resistance in the clinic differs depending on population type and origin, ranging from 4 to 16% (11, 13).

Reports of A. fumigatus azole resistance in Switzerland are rare. A prospective study launched between 2001 and 2003 addressed the occurrence of azole resistance in isolates from clinical and environmental samples. Among the isolates recovered (n = 550), only two exhibited ITZ resistance (14, 15). This result was obtained with a neutral selection of isolates from available samples, which were systematically analyzed for azole susceptibility. We report here a novel study in which isolates were recovered from clinical and environmental samples from a small geographical area in Switzerland. Samples were analyzed for the presence of azole-resistant isolates by a widely used positive-selection procedure. Following this, screening for azole-resistant A. fumigatus was implemented at the Geneva University Hospital (HUG), and as a result, two strains of A. fumigatus with TR34/L98H were identified in two different patients with cystic fibrosis (CF).

**RESULTS**

**Environmental isolates.** Sixty-four samples of different environmental origins comprising a variety of sources (compost sites, public/private gardens, vineyard and agriculture soils, and commercial soil samples) were collected in the western part of Switzerland (the region of Geneva, Lausanne, and Neuchâtel) in a 4-month period (August to December 2015) (see Table S1 in the supplemental material). Six of the 64 samples (9.3%) showed the growth of A. fumigatus colonies on Sabouraud dextrose agar with 4 μg/ml ITZ (SabITZ); 5 A. fumigatus isolates (5d, 15a, 15f, 37c, and 50a) from these samples were VIPcheck positive, confirming that they were ITZ and VRZ resistant. The isolates were further analyzed by matrix-assisted laser desorption ionization—time of flight (MALDI-TOF) mass spectrometry (MS) to confirm their species assignment, and all were identified as A. fumigatus. Susceptibility testing of the A. fumigatus isolates was next performed (by the Sensititre YeastOne [SYO] and CLSI methods) and showed distinct patterns of resistance (Table 1). While all the isolates but one (isolate 61) were

| Isolate | Origin          | Sample type                        | MIC (μg/ml) by: YeastOne | Sensititre test | CLSI M38 method | cyp51A mutation | CSP1 type |
|---------|-----------------|------------------------------------|--------------------------|-----------------|-----------------|-----------------|-----------|
|         |                 |                                    |                          | ITZ VRZ POS     | ITZ VRZ POS     |                 |           |
| 5d      | Environment     | Commercial vineyard soil mix       | >16 0.25 1              | >16 0.25 2      | G54R t01        |                 |           |
| 15a     | Environment     | Compost sample                     | >16 >8 1                | 16 2 1          | TR46/L98H t02   |                 |           |
| 15f     | Environment     | Compost sample                     | >16 4 0.25              | >16 4 1          | TR46/L98H t11   |                 |           |
| 37c     | Environment     | Compost sample                     | >16 2 0.25              | 16 2 1          | TR46/L98H t02   |                 |           |
| 50a     | Environment     | Soil sample                        | >16 4 0.25              | >16 2 1          | TR46/L98H t02   |                 |           |
| 61      | Environment     | Commercial soil sample             | 1 0.5 0.125             | 1 0.5 0.25      | TR46/L98H t03   |                 |           |
| 37a     | Environment     | Compost sample                     | 0.25 0.25 0.06          | 0.25 0.25 0.125 | WT t03          |                 |           |
| 20089320| Patient         | Bronchoalveolar lavage fluid       | >16 2 0.25              | >16 4 1          | TR46/L98H t02   |                 |           |
| 17993925| Patient         | Bronchoalveolar lavage fluid       | >16 4 0.25              | >16 4 1          | TR46/L98H t01   |                 |           |

aWT, wild type.
ITZ resistant (MIC, $>16$ $\mu$g/ml), the VRZ and POS MICs differed. One isolate (5d) stood out, since it was still susceptible to VRZ (Table 1). Isolate 61 exhibited an ITZ MIC that was low (1 $\mu$g/ml) but still higher than that of a susceptible control (isolate 37a, with a MIC of 0.25 $\mu$g/ml). The cyp51A gene and its promoter region from these isolates were sequenced to support the antifungal susceptibility results. The sequences obtained were identical to published A. fumigatus cyp51A sequences. These data and separate $\beta$-tubulin sequencing (data not shown) thus confirmed that the isolates belonged to A. fumigatus sensu stricto. As summarized in Table 1, the majority of azole-resistant isolates harbored the TR34/L98H mutation. The exception was isolate 5d, with a G54R substitution in cyp51A. CLSI MIC readings supported the values obtained by the SYO method with two exceptions. Isolate 5d exhibited a VRZ MIC value of $>8$ $\mu$g/ml by the SYO test but 2 $\mu$g/ml by the CLSI method. POS MIC values were, in general, higher for some isolates than the CLSI method (1 $\mu$g/ml) than by the SYO test (in the range of 0.25 $\mu$g/ml), which, however, still categorized these isolates as POS resistant.

Clinical isolates. Given the detection of azole-resistant isolates in the environment, it was decided to prospectively screen A. fumigatus isolates from clinical samples (160 isolates) (see Table S2 in the supplemental material) for azole resistance at the University Hospital of Geneva during a period of about 1 year (2016–2017). We identified two azole-resistant isolates in the sputum samples of CF patients (see case descriptions below). These isolates exhibited ITZ, VRZ, and POS resistance (MICs, $>16$ $\mu$g/ml, 4 $\mu$g/ml, and 0.25 $\mu$g/ml, respectively). Sequencing analysis of cyp51A and $\beta$-tubulin revealed that both isolates exhibited the TR34/L98H mutation; they were classified as A. fumigatus sensu stricto.

CSP1 typing. The CSP1 gene encodes a cell surface protein that is involved in the conidial germination process and in adherence to the extracellular matrix (16). Klaassen and colleagues used CSP1 in order to categorize A. fumigatus strains (17). The typing nomenclature is based on repeat regions found in CSP1, which are classified into 18 CSP1 types. It has been suggested that CSP typing, with a lower discriminatory power than microsatellite analysis, is suitable for typing at the subpopulation level (16). We addressed the relationships among our sampled isolates by this method. CSP1 typing of all isolates showed four different CSP1 types: the TR34/L98H isolates were distributed over the t01, t02, t03, and t11 subtypes, while the G54R isolate belonged to the t01 subtype (Table 1). The azole-susceptible isolate of environmental origin included here belonged to CSP1 subtype t03.

DISCUSSION

A. fumigatus harboring the TR34/L98H mutation, leading to panazole resistance, was first described in the Netherlands in 2008, followed by other countries (7, 12). The overuse of azoles in agriculture was proposed to be the route of selective pressure on A. fumigatus to develop resistance. In addition, Snelders et al. (18) showed by microsatellite typing that cyp51A mutant strains recovered from the environment and from clinical samples clustered together. This likely indicates common ancestors for the two groups of isolates.

The results presented here confirmed previous findings on the occurrence of azole resistance in A. fumigatus (19). Our study confirms the presence of isolates with the TR34/L98H mutation in the environment in the western part of Switzerland. Interestingly, a single substitution mutation (G54R) was detected in an environmental A. fumigatus isolate. Mutations at position G54 are known to be the consequence of long-term azole therapy in patients (19). Two recent publications have also shown the presence of single substitutions in cyp51A from environmental isolates. The G54E mutation was reported for isolates from environmental samples in Romania, India, and Tanzania, and a novel substitution, G54A, was reported in Germany (20, 21). Since the selective agar medium SabITZ contains 4 $\mu$g/ml ITZ, the selection of resistant isolates for which MICs are higher than this concentration can be expected. The TR34/L98H and G54R mutations result effectively in high ITZ MICs ($>16$ $\mu$g/ml). The type of cyp51A mutation has a differential impact on VRZ MICs: while the TR34/L98H mutation invariably results in VRZ resistance (all isolates exhibit...
MIC values of >2 μg/ml), the G54R mutation does not result in VRZ resistance (MIC, 0.25 μg/ml). Interestingly, Bader and colleagues showed that a selective agar medium with a lower ITZ concentration (1 μg/ml) could identify a broader spectrum of mutations (i.e., TR34/L98F/T121F and TR34/L98F/M172I/T289A), which are associated with a lower ITZ MIC (<2 μg/ml) but with the same VRZ and POS MICs (21). Even though the most prevalent environmental mutation is TR34/L98H, the detection of other cyp51A mutations is important. Therefore, the choice of an appropriate selective medium will have a direct impact on the screening of resistance in A. fumigatus.

Susceptibility testing was performed by two methods, which agreed with each other for most recorded values. POS MICs for TR34/L98H isolates were, in general, higher by the CLSI method than by the SYO test. This difference could be due to endpoint reading issues in the SYO approach, which is based on a change in the color of the metabolic indicator (alamarBlue) rather than on visual inspection of turbidity as performed in the CLSI method. Our antifungal susceptibility testing results were comparable to those of previous studies except for one isolate. This particular isolate (isolate 61), with an ITZ MIC of 1 μg/ml by both methods, was interpreted as susceptible according to the CLSI breakpoints. These results reveal that the TR34/L98H mutation is not always correlated with panazole resistance, a pattern consistent with that of a previous study in which the occurrence of TR34/L98H was not strictly associated with ITZ resistance (MIC cutoff, 1 μg/ml) (22). Therefore, the azole susceptibility profile could not be inferred from the detection of the TR34/L98H mutation alone.

In order to assess the relationships among azole-resistant A. fumigatus isolates, two genotyping methods have generally been applied: microsatellite (STRAf) genotyping and CSP1 typing. We identified CSP1 types (t02 and t011) that had already been reported for azole-resistant isolates (21). A. fumigatus isolate 5d (G54R) had CSP1 type t01, which was also associated with a G54W mutation in the study of Bader et al. (21). However, there seems to be no strict association of the CSP1 type with the occurrence of resistance, since CSP type t01 is also found in wild-type isolates (17). In any case, the small number of azole-resistant A. fumigatus isolates in our study cannot support the conclusion that these isolates have a common origin.

The presence of azole-resistant A. fumigatus isolates from patients has been monitored in different parts of the world with different levels of prevalence (23). In 2015, Switzerland participated in the SCARE study (23) using isolates originating from a single hospital center (University of Lausanne). Among the 236 isolates tested, none exhibited azole resistance (23). An older study performed in Switzerland using A. fumigatus isolates mostly from CF patients (n = 400) but originating from different institutions (all before the year 2003) reported a single ITZ-resistant isolate, which was devoid of the TR34/L98H mutation (15). The present study reveals, for the first time in Switzerland, pan-azole-resistant A. fumigatus isolates from CF patients. One particularly noteworthy point was that the records of these patients did not report the use of azoles. This suggests that the source of the azole-resistant isolates may be environmental. This hypothesis was already suggested in a study investigating A. fumigatus azole resistance in CF patients, some of whom were colonized with azole-resistant isolates without prior azole treatment (24).

The isolation of azole-resistant isolates in the Swiss environment is not a surprise per se, given that most European countries have reported the same phenomenon. The worldwide occurrence of azole resistance in A. fumigatus poses several issues, one of which is the management of patients with prior colonization by resistant isolates. Such patients should be identified early enough for the rapid adaptation of antifungal therapy. Continuing surveillance of azole resistance should also be more systematically organized in Switzerland than it is currently (absence of surveillance program), and the medical sector should be kept well informed on the progression of resistance at a nation-wide scale.

MATERIALS AND METHODS

Environmental samples. Sixty-four samples collected from different environments in the Le- manic region (Table S1 in the supplemental material) were positively screened for A. fumigatus ITZ
A. fumigatus Azole Resistance

Antimicrobial Agents and Chemotherapy

resistance using a Sabouraud dextrose agar plate (2%; Becton, Dickinson [BD Difco) supplemented with ITZ at 4 μg/ml (SabiTZ) (Sigma-Aldrich). Each sample was treated as follows before theazole resistance screening procedure. A 1- to 2-g portion of each sample was suspended in an 8-ml solution containing sterile water, 1% Tween 20 (Sigma-Aldrich), and 0.5 g/liter chloramphenicol (Sigma-Aldrich) (25). Each sample was vortexed for 1 min and was then sedimented for 3 h at room temperature according to published recommendations (25). One hundred microliters of the supernatant from the sedimented solution was plated on two Sabouraud dextrose agar plates (2%; BD Difco) and two SabiTZ plates (Sigma-Aldrich). The plates were incubated at 37°C for 72 h and were checked for the growth of Aspergillus complex spp. Fungal colonies isolated on SabiTZ and Sabouraud agar plates were analyzed with a Microflex LT MALDI-TOF MS (Bruker Daltonics) and were identified as A. fumigatus complex with Biotyper software, version 3.0, using the Filamentous Fungi Library, version 1.0 (Bruker Daltonics). Colonies growing on SabiTZ were next screened for resistance using the VIPcheck test, which consists of a 4-well plate containing agar supplemented with threeazole drugs (VRZ at 2 μg/ml, ITZ at 4 μg/ml, and POS at 0.5 μg/ml) and a growth control. The plates were incubated at 37°C for 72 h. A. fumigatus isolates with growth on SabiTZ and the VIPcheck test were isolated for their susceptibility profiles.

Clinical samples. A. fumigatus group species isolated from respiratory samples of CF patients collected mostly during the year 2016–2017 (Table S2 in the supplemental material) were tested for azole resistance. Each isolate was recovered from ~80°C stocks and was grown on Sabouraud maltose agar. The azole resistance pattern was phenotypically tested using the VIPcheck method. Identification of filamentous fungi was carried out on the Microflex LT MALDI-TOF MS (Bruker Daltonics).

Susceptibility testing. A. fumigatus isolates harboring phenotypic resistance to an azole(s) were tested for their susceptibility profiles by the standardized colorimetric microdilution test method, Sensititre YeastOne (SYO) (Thermo Scientific). The test yields MICs for 10 antifungal agents, including ITZ, VRZ, POS, anidulafungin, fluconazole, and amphotericin B. The test was performed according to the manufacturer’s instructions. Briefly, 100 μl from a 0.5 McFarland standard inoculum of A. fumigatus was added to the SYO broth, which contains RPMI medium 1640 (Thermo Scientific), and was vortexed; then 100 μl of the SYO broth was added to each of the 96 wells of the SYO plate. The SYO plate was incubated at 37°C for 48 to 72 h. MICs were determined by changes in the color of alamarBlue as an indicator of metabolic activity.

The susceptibility of A. fumigatus isolates was also determined according to the CLSI M38-A2 method (26). The MIC was defined as the antifungal concentration at which visual growth was completely inhibited. The isolate was regarded as susceptible when the MIC was <2 μg/ml for ITZ and VRC and <0.25 μg/ml for POS, according to the recommendations of Espinel-Ingroff et al. (27). An isolate containing the known cyp51A TR2/L98H mutation (CM2627) was included as a control in susceptibility assays (9).

Sequencing. Isolates with a phenotypic resistance pattern were sequenced for the cyp51A gene. A. fumigatus DNA was extracted using a one-step procedure. The fungal biomass was added to a microcentrifuge tube containing 0.3 g of glass beads (diameter, 0.5 mm), 200 μl phenol-chloroform (Sigma), and 200 μl of breaking buffer (2% Triton X-100, 1% sodium dodecyl sulfate, 10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 100 mM NaCl). After 15 s of shaking at 4,500 rpm using a Precellys Evolution tissue homogenizer (Bertin Instruments, France), samples were centrifuged for 10 min at 13,000 rpm. One microliter of the supernatant was used for PCR.

The cyp51A gene was amplified by PCR using two cyp51A primers (5′-GAGCCGAATGAAGTGGCTTA ATTACTA-3′ and 5′-CCACAGTTTAGATGCTAGAAGAGG-3′). PCR was performed in a 50-μl volume containing 5 μL buffer, thermopol reaction buffer (New England BioLabs), 1 μL deoxynucleoside triphosphates (dNTPs) at 10 mM, 1 μL BSA, 1 μL Taq polymerase at 5,000 U/mL (New England BioLabs), and 1 μL of lysed supernatant containing genomic DNA. PCR products were purified using ExoSAP-IT reagent (Affymetrix). Five microliters of the PCR product was mixed with 2 μl of ExoSAP-IT reagent. The solution was incubated for 15 min at 37°C, followed by a 15-min incubation at 80°C.

PCR products were next sequenced using two sets of primers: CYP51A-A7 (5′-GAGCCGAATGAAGTGGCTTA ATTACTA-3′) and CYP51A-A5 (5′-TCTTGCCAGCGAAAGAAGAC-3′) for tandem repeat detection and Cyp51a_s3q (5′-CAGGTGGCAATCTCCTTGATC-3′) and Cyp51a_q4 (5′-GGCAATGAGGACGTGCAGTGC-3′) for single-site mutation detection. Sequencing used the BigDye Terminator kit (Applied Biosystems, USA). The sequences were analyzed using Geneious software, version 9.16 (Biomatters, New Zealand).

The A. fumigatus β-tubulin gene was amplified with primers tubulin_s (5′-GCTCTGGCCACTACAATG GCT-3′) and tubulin_as (5′-GCTATGGTACAGGGCTCGA-3′). Gene products were purified and sequenced as described above.

CSP1 typing. A. fumigatus isolates were genotyped by CSP1 typing. This subtyping strategy employs comparative DNA sequence analysis of the tandem repeat region of the AFUA_3G08890 gene (17). The CSP1 gene was amplified by PCR using two CSP1 primers proposed by Klaassen et al. (17): 5′-TTGGGT GCCATTTGGCCAA-3′ and 5′-GAGCCGAATGAAGAAGAC-3′. After PCR, the products were sequenced as described above using the same primers as those used for the amplification. Geneious software was used to analyze results.

Case reports. Case 1 concerns a 52-year-old woman. She was diagnosed with homozygous Phe-S08del mutation CF when she was 38 years old. She is known to have severe airflow obstruction (predicted forced expiratory volume in 1 second [FEV1] value, 31%) with severe diffuse bronchiectasis and chronic infection by methicillin-susceptible Staphylococcus aureus (MSSA), Achromobacter xylosoxids, and Stenotrophomonas maltophilia. This chronic respiratory infection is complicated by acute respiratory exacerbations necessitating intravenous antibiotic cures 2 to 3 times per year. Additionally,
she recently received a successful 18-month course of antimycobacterial medication (rifabutin, clarithromycin, and ethambutol) for Mycobacterium avium-associated pulmonary disease. She has demonstrated chronic respiratory colonization with A. fumigatus since CF diagnosis but has never developed active Aspergillus infection or ABPA. Her total IgE level is undetectable. She has never received antifungal therapy, including triazoles. Her regular treatment is based on oral pancreatin, liposoluble vitamin supplementation, and ursodeoxycholic acid and inhaled budesonide, formoterol, and dornase alpha. In addition, she follows a twice-weekly physical treatment program for respiratory secretion drainage with a physiotherapist. Since the patient is already presenting severe alteration in lung function, which is still declining, double lung transplantation will be considered mandatory in the coming years.

Case 2 concerns a 27-year-old man. He was diagnosed with homozygous Phe-508del mutation CF when he was born due to meconium ileus, requiring surgery. He is known to have stable mild airflow obstruction (predicted FEV1 value, 82%) and mild diffuse bronchiectasis with chronic respiratory colonization with A. fumigatus since January 2016. He has never developed active aspergillus infection or ABPA. His total IgE level measurements have remained between 15 and 21.9 kU/liter during the past 24 months (normal value, <100 kU/liter). He has never received antifungal therapy, including triazoles. His treatment is based on oral pancreatin, liposoluble vitamin supplementation, and ursodeoxycholic acid and inhaled fluticasone propionate and salbutamol. In addition, he follows a weekly physical treatment program for respiratory secretion drainage with a physiotherapist.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/AAC.02088-17.

**SUPPLEMENTAL FILE 1,** XLSX file, 0.1 MB.

**SUPPLEMENTAL FILE 2,** XLSX file, 0.1 MB.

**ACKNOWLEDGMENTS**

D.S. is supported by Swiss National Research grant 31003A_172958.

We thank Françoise Ischer, Valérie Barras, Didier Schorderet, and José Fernandez for technical assistance and F. Lamoth and M. Arauanno for advice on susceptibility testing.

**REFERENCES**

1. Dagenais TR, Keller NP. 2009. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev 22:447–465. https://doi.org/10.1128/CMR.00055-08.

2. Denning DW, Lee KY, Hostettler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144. https://doi.org/10.1016/0002-9343(94)90023-X.

3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestreicher MW, Kern WV, Ramar KA, Ribaudo P, Lortholary O, Sylvester R, Rubín RH, Wingard JR, Stark P, Durand C, Caillot D, Thié E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415. https://doi.org/10.1056/NEJMoa021091.

4. Walsh TJ, Anaisse EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360. https://doi.org/10.1086/525258.

5. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Hoffrog GD, Holowiec JK, Stockelberg D, Goh YT, Petreni M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole in the treatment of aspergillosis. N Engl J Med 356:348–359. https://doi.org/10.1056/NEJMoa061094.

6. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoum M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, III, Lee M, Maher RM, Schmitt-Hoffmann AH, Zehir B, Ullmann AJ. 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387:760–769. https://doi.org/10.1016/S0140-6736(15)01159-9.

7. Nieders E, van der Lee HA, Kuipers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5:e219. https://doi.org/10.1371/journal.pmed.0050219.

8. Camps SM, Rijs AJ, Klaassen CH, Meis JF, O’Gorman CM, Dyer PS, Melchers WJ, Verweij PE. 2012. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 50:2674–2680. https://doi.org/10.1128/JCM.03335-12.

9. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, Rodriguez-Tudela JL. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51:1897–1904. https://doi.org/10.1128/AAC.01092-06.

10. Vermeulen E, Lagrou K, Verweij PE. 2013. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 26:493–500. https://doi.org/10.1097/QCO.0000000000000005.

11. Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. 2016. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci 371:20150460. https://doi.org/10.1098/rstb.2015.0460.

12. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. 2016. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 62:362–368. https://doi.org/10.1093/cid/civ885.

13. Verweij PE, Zhang J, Debets AJ, Meis JF, van de Veerdonk FL, Schoustra SE, Zwaan BJ, Melchers WJ. 2016. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis 16:e251–e260. https://doi.org/10.1016/S1473-3099(16)30138-4.
14. Meneau I, Coste AT, Sanglard D. 2016. Identification of Aspergillus fumigatus multidrug transporter genes and their potential involvement in antifungal resistance. Med Mycol 54:616–627. https://doi.org/10.1093/mmy/myw005.

15. Meneau I, Sanglard D. 2005. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 43(Suppl 1):S307–S311. https://doi.org/10.1080/13693780500090826.

16. Levadny E, Romano J, Shadkchan Y, Sharon H, Verstrepen KJ, Fink GR, Osherov N. 2007. Coding tandem repeats generate diversity in Aspergillus fumigatus genes. Eukaryot Cell 6:1380–1391. https://doi.org/10.1128/EC.00229-06.

17. Klaassen CH, de Valk HA, Balajee SA, Meis JF. 2009. Utility of CSP typing to sub-type clinical Aspergillus fumigatus isolates and proposal for a new CSP type nomenclature. J Microbiol Methods 77:292–296. https://doi.org/10.1016/j.mimet.2009.03.004.

18. Snelders E, Huis In ’t Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75:4053–4057. https://doi.org/10.1128/AEM.00231-09.

19. Vermeulen E, Cooreman S, Maertens J, Jeurissen A, Lagrou K. 2012. Azole resistance in Aspergillus: an emerging problem? Acta Clin Belg 67:322–327.

20. Sharma C, Hagen F, Moroti R, Meis JF, Chowdhary A. 2015. Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: is it de novo or environmentally acquired? J Glob Antimicrob Resist 3:69–74. https://doi.org/10.1016/j.jgar.2015.01.005.

21. Bader O, Tunnermann J, Dudakova A, Tangwattanachuleeporn M, Weig M, Gross U. 2015. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother 59:4356–4359. https://doi.org/10.1128/AAC.00100-15.

22. van Ingen J, van der Lee HA, Rijjs TA, Leenstra T, Melchers WJ, Verweij PE. 2015. Azole, polyene and echinocandin MIC distributions for wild-type, TR46/L98H and TR34/L98H isolates in the Netherlands. J Antimicrob Chemother 70:178–181. https://doi.org/10.1093/jac/dku364.

23. van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, Chrysanthou E, Mellado E, Kidd SE, Tortorano AM, Dannaoui E, Gaudard P, Baddley JW, Uekotter A, Grillo A, Claas EC, Klimko N, Moore CB, Denning DW, Pasqualotto AC, Kibbler C, Arikan-Akdagli S, Andes D, Meletiadis J, Naumuk L, Nucci M, Melchers WJ, Verweij PE. 2015. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 21:1041–1044. https://doi.org/10.3201/eid2106.140717.

24. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Kronke M, Hamburger P, Meis JF, Ciavarella E, Rinaldi MG, Torrance C, Baddley JW. 2014. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 69:1533–1536. https://doi.org/10.1093/jac/dku009.

25. Prigiotano A, Venier V, Cogliati M, De Lorenzis G, Esposto MC, Tortorano AM. 2014. Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012. Euro Surveill 19:20747. https://doi.org/10.2807/1560-7917.ES2014.19.12.20747.

26. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, CLSI document M38-A2, 2nd ed. CLSI, Wayne, PA.

27. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pfaller MA, Rinaldi MG, Canton E, Sader HS, Turco P, Turner J. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 48:3251–3257. https://doi.org/10.1128/JCM.00536-10.